One-year outcome of neovascular age-related macular degeneration patients followed-up using different optical coherence tomography modalities. Issue 6 (November 2022)

• Record Type: Journal Article
• Authors: Sukkarieh, Georges; Vasseur, Vivien; Lejoyeux, Raphaël; Wolff, Benjamin; Mauget-Faÿsse, Martine
• Is Part Of: European journal of ophthalmology. Volume 32:Issue 6(2022)
• Page Start: 3503
• Page End: 3509
• Publication Date: 2022-11
• Subjects: neovascular age-related macular degeneration -- optical coherence tomography b-scan -- optical coherence tomography angiography -- anti-vascular endothelial growth factor; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.1177/11206721221088260
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: The aim of this study is to compare the one year outcome of neovascular age-related macular degeneration (nAMD) patients treated by a PRN regimen of Anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVTs), using optical coherence tomography B-scan (OCT-B) or OCT Angiography (OCT-A) imaging modalities during follow-up. Methods: Patients older than 50 years with nAMD currently treated by PRN regimen of Anti-VEGF IVTs were recruited from Rothschild Foundation Hospital – Paris and Centre Ophtalmologique Maison Rouge – Strasbourg and followed-up for a year. Patients were randomized in two groups: one group was followed by OCT-B while the other was followed by OCT-A. Results: Thirty-three patients were followed by OCT-A and 31 patients were followed by OCT-B. Twenty-nine patients in the OCT-A group and 27 patients in the OCT-B group attended the last visit. No statistically significant difference was found between the two groups at 1 year concerning: improvement or stabilization of the best corrected distance visual acuity (BCVA) (p > 0.9), exudative signs (p > 0.9), number of injections (p = 0.8) and the delay until the first reinjection was performed (p = 0.5). Conclusion: The use of OCT-A or OCT-B as imaging modalities in nAMD treated by a PRN regimen of Anti-VEGF IVTs seem to be comparable at one year.